AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients

AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients

Έγκριση FDA σε 10η ένδειξη του Imbruvica της AbbVie και Johnson

Έγκριση FDA σε 10η ένδειξη του Imbruvica της AbbVie και Johnson

Pfizer secures 4th cancer drug approval in 2 months

Pfizer secures 4th cancer drug approval in 2 months

AbbVie and Genentech Snag Accelerated Approval for Venclexta in AML

AbbVie and Genentech Snag Accelerated Approval for Venclexta in AML

Νέα θεραπευτική επιλογή για αιματολογική κακοήθεια

Νέα θεραπευτική επιλογή για αιματολογική κακοήθεια

AbbVie HCV Revenue Surprises Again, But Falloff Is Coming

  As AbbVie Inc. continues to report Humira growth and investors continue to worry about biosimilar competition, the Chicago-area pharma offered a surprise when it presented its second quarter earnings: a better-than-expected performance for the hepatitis C franchise, bringing it on par with rival Gilead Sciences Inc.. Overviewing its second quarter financials July 27, AbbVie reported that its HCV franchise, … Συνεχίστε να διαβάζετε AbbVie HCV Revenue Surprises Again, But Falloff Is Coming.